Journal article
Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer
Abstract
BACKGROUND: Previous studies have shown that metastatic colorectal carcinoma (mCRC) patients treated with bevacizumab, experience variation in the plasma levels of angiogenesis growth factors and related cytokines, called angiogenic switch (AS). The aim of the present study was to analyze the relationship between AS and the clinical response during standard chemotherapy-bevacizumab treatment.
PATIENTS AND METHODS: Patients with Eastern …
Authors
Cubillo A; Álvarez-Gallego R; Muñoz M; Pond G; Perea S; Sánchez G; Martin M; Rodríguez-Pascual J; Garralda E; Vega E
Journal
American Journal of Clinical Oncology, Vol. 42, No. 1, pp. 56–59
Publisher
Wolters Kluwer
Publication Date
1 2019
DOI
10.1097/coc.0000000000000474
ISSN
0277-3732